Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...
video

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

Transfusion with cryopreserved platelets may offer superior bleeding control for thrombocytopenic patients. Dr. Schlicter shares results from a phase I study, and gives a...
video

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

Dr. Pipe, a speaker in the Special Education Session on Newly Approved Drugs, reviews what clinicians need to know about coagulation factor IX (recombinant)/antihemophilic...
video

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
video

Crystal Mackall, MD: Passing the Checkpoint With New Approaches to Immunotherapy

Checkpoint blockade is revolutionizing immunotherapy, but there is room for improvement. Dr. Mackall, who chaired a session on “Novel Approaches to Immunotherapy,” speaks about...
video

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

Transfusion with cryopreserved platelets may offer superior bleeding control for thrombocytopenic patients. Dr. Schlicter shares results from a phase I study, and gives a...
video

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

Dr. Pipe, a speaker in the Special Education Session on Newly Approved Drugs, reviews what clinicians need to know about coagulation factor IX (recombinant)/antihemophilic...
video

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
video

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

Dr. Jackson shares results from the phase III Myeloma XI study, which compared patients treated with lenalidomide maintenance therapy or no maintenance therapy in...
video

Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma

Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.